KEAP1 and goiter: In terms of clinical implications, they may have relevance for humans with functional genetic variation in NFE2L2 [22] or KEAP1 [23] or under treatment with clinically approved NRF2 modulating drugs (i.e., dimethyl fumarate [24] and ovameloxolone [25]); it will be relevant to examine whether individuals with genetically or pharmacologically activated Nrf2 signaling are more susceptible to thyroid diseases such as goiter.